Live
Lonza NewsStipple Bio Enters Multi-Target License Agreement with Lonza to Advance Precision Oncology ADC Therapies - The Manila TimesEndpoints NewsParabilis Medicines charts $413M IPO to back peptide pipelineFierceBiotechInnovent, fresh from $1.2B deal, posts phase 3 win for Takeda-partnered ADCPharmaVoiceHouse bill aims to crack down on China biotech dealsPharmaVoicePharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?FierceBiotechMedline earns FDA warning letter ire for repeated toxic bacteria problemsFierceBiotechFrom business strategy to CAR-T responses, for Cabaletta it’s all about ‘durability’BrukerBruker showcases expanded microbiology diagnostics portfolio - Investing.comBrukerBruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026 - 巴士的報Endpoints NewsADC Therapeutics' confirmatory data for Zynlonta muddied by death ratesEli LillyEli Lilly continues genetic medicine push with $1.9bn Ascidian partnership - Pharmaceutical TechnologyEli LillyEli Lilly forms billion-dollar genetic kidney disease partnership with US biotech Ascidian Therapeutics - medwatch.com
Endpoints News Feb 27, 2026

Novartis closes Avidity deal as rare heart disease spinout launches

Novartis closes Avidity deal as rare heart disease spinout launches

Original
Body unavailable. Use the original source.